JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB22717

Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)]

4

(6 Reviews)

|

(31 Publications)

Mouse Monoclonal Cytochrome P450 1A2 antibody. Suitable for IHC-P, Flow Cyt, WB, ICC/IF and reacts with Human, Mouse, Rat samples. Cited in 31 publications. Immunogen corresponding to Full Length Protein corresponding to Rat Cyp1a2.

View Alternative Names

Cyp1a-2, Cyp1a2, Cytochrome P450 1A2, CYPIA2, Cholesterol 25-hydroxylase, Cytochrome P-448, Cytochrome P-450d, Cytochrome P450-D, Hydroperoxy icosatetraenoate dehydratase

5 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)

ab22717 staining human normal liver. Staining is localised to the cytoplasm.
Left panel : with primary antibody at 1 ug/ml. Right panel : isotype control.
Sections were stained using an automated system DAKO Autostainer Plus , at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 antigen retrieval buffer citrate pH 6.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.

Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)

ICC/IF image of ab22717 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab22717, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Flow Cytometry - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)

Overlay histogram showing MCF7 cells stained with ab22717 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab22717, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

Western blot - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)
  • WB

AbReview25313****

Western blot - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)

All lanes:

Western blot - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (ab22717) at 1/2500 dilution

All lanes:

Tissue lysate prepared from murine liver microsomes at 10 µg

Secondary

All lanes:

Goat anti-mouse IgG(H+L)-HRP conjugate at 1/5000 dilution

Predicted band size: 58 kDa

true

Exposure time: 1s

Image courtesy of an anonymous Abreview.

Western blot - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)
  • WB

Unknown

Western blot - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (AB22717)

All lanes:

Western blot - Anti-Cytochrome P450 1A2 antibody [d15 (16VII F10F12)] (ab22717) at 1 µg/mL

Lane 1:

Human liver tissue lysate - total protein (<a href='/en-us/products/unavailable/human-liver-tissue-lysate-total-protein-ab29889'>ab29889</a>) at 10 µg

Lane 2:

Liver (Mouse) Tissue Lysate at 10 µg

Lane 3:

Liver (Rat) Tissue Lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Mouse IgG H&L (HRP) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-hrp-preadsorbed-ab97040'>ab97040</a>) at 1/5000 dilution

Predicted band size: 58 kDa

Observed band size: 30 kDa,48 kDa,58 kDa

true

Exposure time: 150s

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

d15 (16VII F10F12)

Isotype

IgG1

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

WB, ICC/IF, IHC-P, Flow Cyt

applications

Immunogen

Full Length Protein corresponding to Rat Cyp1a2. The exact immunogen used to generate this antibody is proprietary information.

P04799

Specificity

This antibody cross reacts with CYP 1A1. This antibody does not react with rat CYP 2A1, 2B1, 2B2, 2C6, 2C7, 2C11, 4A1, 4A2 and 4A3.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "4 µg/mL", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1 µg for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/mouse-igg1-kappa-monoclonal-15-6e10a7-isotype-control-ab170190'>ab170190</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1-5 µg/mL", "ICCIF-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCyt-species-checked": "guaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCyt-species-checked": "guaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

Isotype

IgG1/IgG2a kappa

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A/G
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome P450 1A2 often known as CYP1A2 is an important enzyme in the cytochrome P450 superfamily with a known mass around 58 kDa. It is mainly expressed in the liver where it functions in the metabolism of drugs and the bioactivation of various compounds. CYP1A2 also participates in the oxidation of small organic molecules which include xenobiotics and endogenous substrates. Due to its function researchers frequently study CYP1A2 substrates and its inhibitors to understand better its role in drug metabolism and toxicity.
Biological function summary

CYP1A2 plays a central role in the oxidative biotransformation of drugs and procarcinogens. It does not form part of a larger complex but interacts dynamically with other enzymes in the detoxification process. CYP1A2 metabolizes several clinical drugs such as caffeine and theophylline and regulates the detoxification of aromatic amines and hydrocarbons. Studying CYP1A2 inhibitors can provide insights into clinically relevant drug interactions and potential side effects in pharmacotherapy.

Pathways

CYP1A2 functions within the drug metabolism and synthesis of cholesterol steroids and other lipids pathways. In the drug metabolism pathway CYP1A2 works alongside other cytochrome P450 enzymes such as CYP1A1 and CYP1B1 which together ensure the metabolism and clearance of various exogenous and endogenous compounds. These pathways are vital for maintaining drug efficacy and preventing toxicity through the metabolic clearance of pharmaceutical agents and harmful substances.

CYP1A2 activity links to liver disorders and certain cancers. Altered enzyme activity may lead to hepatotoxicity a condition that arises from excessive accumulation of active drug metabolites in the liver. Furthermore due to its role in activating procarcinogens increased CYP1A2 activity relates to a higher risk of developing certain cancers including liver cancer. Researchers often explore these connections to better understand the enzyme's role in disease pathogenesis and to develop CYP1A2-directed therapies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid. Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer. Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA. May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin. Metabolizes caffeine via N3-demethylation.
See full target information Cyp1a2

Publications (31)

Recent publications for all applications. Explore the full list and refine your search

British journal of pharmacology 180:2973-2988 PubMed37403641

2023

Role of circadian clock in the chronoefficacy and chronotoxicity of clopidogrel.

Applications

Unspecified application

Species

Unspecified reactive species

Luyao Ma,Fangjun Yu,Di He,Lianxia Guo,Yu Yang,Wangchun Li,Tianpeng Zhang

Frontiers in genetics 14:1151340 PubMed37035728

2023

Multi-omics analysis revealed the role of CYP1A2 in the induction of mechanical allodynia in type 1 diabetes.

Applications

Unspecified application

Species

Unspecified reactive species

Hongjin Chen,Chenlong Liao,Xiaosheng Yang,Han Zhou,Yiwei Wu,Qiuyang Sun,Shuo Li,Wenchuan Zhang

Acta pharmaceutica Sinica. B 13:648-661 PubMed36873188

2023

The role of CYP1A1/2 in cholesterol ester accumulation provides a new perspective for the treatment of hypercholesterolemia.

Applications

Unspecified application

Species

Unspecified reactive species

Jian Lu,Xuyang Shang,Bingyi Yao,Dongyi Sun,Jie Liu,Yuanjin Zhang,He Wang,Jingru Shi,Huaqing Chen,Tieliu Shi,Mingyao Liu,Xin Wang

Scientific reports 12:21825 PubMed36528753

2022

Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism.

Applications

Unspecified application

Species

Unspecified reactive species

Mohamed Albadry,Sebastian Höpfl,Nadia Ehteshamzad,Matthias König,Michael Böttcher,Jasna Neumann,Amelie Lupp,Olaf Dirsch,Nicole Radde,Bruno Christ,Madlen Christ,Lars Ole Schwen,Hendrik Laue,Robert Klopfleisch,Uta Dahmen

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 181:106358 PubMed36513193

2022

The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Xuan Qin,Cen Xie,John M Hakenjos,Kevin R MacKenzie,Shelton R Boyd,Mercedes Barzi,Karl-Dimiter Bissig,Damian W Young,Feng Li

Nature communications 13:7345 PubMed36446858

2022

IL6 supports long-term expansion of hepatocytes in vitro.

Applications

Unspecified application

Species

Unspecified reactive species

Ren Guo,Mengmeng Jiang,Gang Wang,Bing Li,Xiaohui Jia,Yan Ai,Shanshan Chen,Peilan Tang,Aijie Liu,Qianting Yuan,Xin Xie

Evidence-based complementary and alternative medicine : eCAM 2022:2481654 PubMed36285162

2022

Mechanisms Underlying the Differences in the Pharmacokinetics of Six Active Constituents of Huangqi Liuyi Decoction between Normal and Diabetic Nephropathy Mouse Models.

Applications

Unspecified application

Species

Unspecified reactive species

Qun Wang,Yonglin Wang,Wen Liu,Dingyan Lu,Yang Jin,Nian Tang,Ya Shi,Zipeng Gong,Weiyi Tian,Ting Liu

Frontiers in pharmacology 13:977370 PubMed36188572

2022

Regulation of CYP450 and drug transporter mediated by gut microbiota under high-altitude hypoxia.

Applications

Unspecified application

Species

Unspecified reactive species

Xue Bai,Jianxin Yang,Guiqin Liu,Junbo Zhu,Qian Wang,Wenqi Gu,Linli La,Xiangyang Li

Nature communications 13:3317 PubMed35680907

2022

Molecularly cleavable bioinks facilitate high-performance digital light processing-based bioprinting of functional volumetric soft tissues.

Applications

Unspecified application

Species

Unspecified reactive species

Mian Wang,Wanlu Li,Jin Hao,Arthur Gonzales,Zhibo Zhao,Regina Sanchez Flores,Xiao Kuang,Xuan Mu,Terry Ching,Guosheng Tang,Zeyu Luo,Carlos Ezio Garciamendez-Mijares,Jugal Kishore Sahoo,Michael F Wells,Gengle Niu,Prajwal Agrawal,Alfredo Quiñones-Hinojosa,Kevin Eggan,Yu Shrike Zhang

EBioMedicine 66:103307 PubMed33819741

2021

The gut microbiome influences the bioavailability of olanzapine in rats.

Applications

Unspecified application

Species

Unspecified reactive species

Sofia Cussotto,Jacinta Walsh,Anna V Golubeva,Alexander V Zhdanov,Conall R Strain,Fiona Fouhy,Catherine Stanton,Timothy G Dinan,Niall P Hyland,Gerard Clarke,John F Cryan,Brendan T Griffin
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com